Astellas Pharma ( (JP:4503) ) has provided an announcement.
Astellas Pharma reported an increase in other income due to changes in the fair value of contingent consideration related to its clinical development plans and program discontinuations. The company’s actual financial results for the fiscal year ended March 31, 2025, exceeded forecasts, with significant increases in operating profit and profit before tax, reflecting strong operational performance.
More about Astellas Pharma
Astellas is a global life sciences company focused on transforming innovative science into value for patients. The company provides transformative therapies in areas such as oncology, ophthalmology, urology, immunology, and women’s health, addressing diseases with high unmet medical needs.
YTD Price Performance: -7.80%
Average Trading Volume: 4,001
Technical Sentiment Signal: Buy
Current Market Cap: $17.15B
For a thorough assessment of 4503 stock, go to TipRanks’ Stock Analysis page.